Revised. Amendments from Version 1
==================================

We performed new experiments to address a comment raised by Dr. Kirley. These data are shown in a new figure (\#9). In addition, we revised the manuscript in several locations of the \'Results and discussion\' and \'Conclusions\' to address additional comments.

Introduction
============

Nucleotides like ATP are released from neurons and glia throughout the nervous system in response to physiological and pathological stimuli ( [@ref-2]; [@ref-15]; [@ref-26]; [@ref-30]). Nucleotides signal through activation of the purinergic P2X and P2Y receptors and can excite or sensitize nociceptive neurons ( [@ref-8]; [@ref-12]; [@ref-35]; [@ref-46]). The actions of extracellular ATP can be terminated by several membrane-bound and secreted ectonucleotidases that hydrolyze ATP into adenosine ( [@ref-39]; [@ref-41]; [@ref-42]; [@ref-48]; [@ref-53]; [@ref-56]). Adenosine, in turn, can signal through the A ~1~ adenosine receptor (A ~1~R) to inhibit the activity of nociceptive neurons in the spinal cord ( [@ref-36]; [@ref-54]).

We previously identified and characterized the ectonucleotidases that hydrolyze AMP in nociceptive neurons ( [Figure 1](#f1){ref-type="fig"}). These enzymes are Prostatic acid phosphatase (PAP; ( [@ref-42]; [@ref-56])), Ecto-5'-nucleotidase (NT5E; ( [@ref-39]; [@ref-42])), and Tissue-nonspecific alkaline phosphatase (TNAP; ( [@ref-41])). Pharmacological and knockout mouse model studies suggest that each of these enzymes contributes to the production of adenosine from AMP in the dorsal spinal cord, where nociceptive neurons synapse with spinal neurons ( [@ref-41]). Further, knockout mice lacking PAP, NT5E, or both PAP and NT5E showed enhanced nociceptive sensitization in models of chronic pain ( [@ref-39]; [@ref-42]; [@ref-56]). While NT5E hydrolyzes AMP into adenosine (optimal activity at neutral pH), PAP (at neutral and acidic pHs) and TNAP (at basic pH) can also hydrolyze ATP, ADP, and AMP ( [@ref-10]; [@ref-40]; [@ref-41]; [@ref-53]). Others found that ectonucleoside triphosphate diphosphohydrolases (ENTPDs), an additional class of ectonucleotidases, might also be responsible for hydrolyzing ATP and ADP in primary somatosensory neurons ( [@ref-48]).

![Ectonucleotidases, their substrates, and products.\
Several ectonucleotidases, depicted here, have been shown to hydrolyze adenosine-containing extracellular nucleotides such as ATP in a stepwise process into adenosine.](f1000research-3-5673-g0000){#f1}

In the ENTPD family, four (ENTPD1, -2, -3, and -8) are membrane-bound enzymes that hydrolyze extracellular ATP and ADP ( [@ref-32]). ENTPD1, -2, and -3 are expressed throughout the central nervous system and display different preferences and kinetics for each nucleotide substrate ( [@ref-18]; [@ref-19]). The hydrolysis of ATP by ENTPD1 results in an increase in AMP levels, suggesting ENTPD1 rapidly hydrolyzes ATP and ADP substrates, whereas ENTPD2 preferentially dephosphorylates ATP, resulting in a buildup of extracellular ADP ( [Figure 1](#f1){ref-type="fig"}). In contrast, ENTPD3 displays an intermediate activity between ENTPD1 and -2, showing rapid hydrolysis of ATP and transient increases in ADP before conversion into AMP ( [@ref-18]). ENTPD1, -2, and -3 are expressed at similar levels in different cell types of the DRG and spinal cord ( [@ref-33]; [@ref-48]). Specifically, ENTPD1 is primarily expressed in blood vessels, ENTPD2 is primarily expressed in glial cells, including satellite cells and non-myelinating Schwann cells, and ENTPD3 is preferentially expressed in DRG neurons and their central and peripheral projections ( [@ref-6]; [@ref-48]). Further, ENTPD3 co-localizes with markers of nociceptive neurons, such as TRPV1, NT5E, and IB4-binding ( [@ref-48]). These findings suggested that ENTPD3 might contribute to ATP and ADP hydrolysis in nociceptive neurons ( [@ref-48]).

To study the contribution of ENTPD3 to ATP and ADP hydrolysis in nociceptive and non-nociceptive neurons in the DRG, we generated a knockout mouse that globally lacked ENTPD3 protein. As part of these studies, we performed immunohistochemical experiments to determine which subsets of DRG neurons expressed ENTPD3 and how loss of ENTPD3 altered nucleotide hydrolysis and nociceptive behaviors. Fast-scan cyclic voltammetry (FSCV) was used to examine adenosine generation in wild-type (WT) and *Entpd3* ^-/-^ mice. We found no significant differences between WT and *Entpd3 ^-/-^* mice in assays of ectonucleotidase function or in nociceptive behavioral assays, suggesting that additional enzymes are involved in the hydrolysis of ATP and ADP in nociceptive and non-nociceptive neurons.

Methods
=======

Animal care and use
-------------------

All vertebrate animals and procedures used in this study were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. Mice were maintained on a 12 h:12 h light:dark cycle, were given food (Harlan 2920X) and water ad libitum, and were tested during the light phase. Mice were acclimated to the testing room, equipment and experimenter 1--3 days prior to testing.

Molecular biology and knockout mouse generation
-----------------------------------------------

Recombineering was used to generate the *Entpd3* targeting arms from a 129S7/SvEv-derived bacterial artificial chromosome (BAC; bMQ-111o06; CHORI). The start codon, located in exon 2 ( [@ref-23]), was replaced with an *AscI* site to facilitate cloning of *AscI*-LoxP-EGFPf-3xpA-LoxP-DTR-pA-Frt-PGK-NeoR-Frt- *AscI*. EGFPf=farnesylated enhanced GFP ( [@ref-55]), DTR=human diptheria toxin receptor ( [@ref-34]). Use of this construct for axonal tracing and cell ablation of calcitonin gene-related peptide (CGRP)-expressing DRG neurons was previously described ( [@ref-28]; [@ref-19]). Correct targeting was confirmed in 5.2% of all embryonic stem cell clones by Southern blotting using flanking 5' and 3' probes and a NeoR internal probe. High percentage chimeras were crossed to C57BL/6 females to establish germline transmission and then crossed to PGK1-FLPo mice \[B6(C3)-Tg(Pgk1-FLPo)10Sykr/J, Jackson Laboratory\] to remove the Frt-flanked selection cassette (confirmed by PCR). Mice were backcrossed to C57BL/6 mice for eight generations to remove the PGK1-FLPo allele (confirmed by PCR) and establish the *Entpd3 ^-/-^* line. Note, the knocked-in GFP was undetectable in DRG and spinal cord neurons of the *Entpd3 ^-/-^* line.

Immunoblotting
--------------

Male WT and *Entpd3 ^-/-^* (3 month-old; \~25 g; n=3 for each genotype) were decapitated, and the DRG and bladder tissue was collected and digested in modified RIPA buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% SDS, 0.5% deoxycholate) supplemented with protease inhibitors (Roche Complete Mini). Protein samples from the cell lysate (1 mg/ml) were analyzed by SDS-PAGE with 4--20% gradient Tris-Glycine polyacrylamide gels (BioRad). The protein samples were then transferred to a polyvinylidene difluoride membrane and probed with a sheep anti-ENTPD3 polyclonal antibody overnight at 4°C (0.2 μg/ml; AF4464, R&D Systems), followed by a rabbit anti-sheep horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature (0.16 μg/ml; \#31480, Thermo Scientific).

Tissue collection and preparation for histology
-----------------------------------------------

Hindpaw skin (glabrous and hairy), lumbar DRGs, and spinal cords were removed from male mice (n=3; \~10 weeks old) following decapitation, and immersion-fixed in cold 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 3 h, 4 h, and 8 h, respectively, and then cryoprotected in 30% sucrose in 0.1 M phosphate buffer at 4°C. DRGs were sectioned at 20 µm and collected on SuperFrost Plus slides; spinal cords and hindpaw skin were sectioned at 30 µm and 60 µm, respectively, and collected in PBS or a cryoprotectant solution containing PBS, ethylene glycol, and glycerol for long-term storage at -20°C.

Histochemistry
--------------

Enzyme histochemistry was performed as described previously ( [@ref-56]) with a few modifications. Sections of DRG and spinal cord from 3 WT and 3 *Entpd3 ^-/-^* mice were incubated with a given concentration of a nucleotide (AMP, 6 mM for DRG, 3 mM for spinal cord; ADP, 1 mM for DRG and spinal cord; ATP, 0.2 mM for DRGs and spinal cord; UTP, 0.2 mM for spinal cord) in Trizma-maleate buffer containing 20 mM MgCl ~2~, pH 7.0, and 2.4 mM lead nitrate for 3 h at room temperature. For some experiments, we included (in the rinse and substrate incubation steps) 10 mM levamisole to block alkaline phosphatase activity, 5 mM ouabain to block Na+/K+-ATPases, a combination of levamisole and ouabain, or 0.1--1.0 mM ARL67156 ( *N*-diethyl- [d]{.smallcaps}-β,γ-dibromomethylene ATP) to nonselectively block ENTPD enzymes. All reagents were purchased from Sigma.

Immunohistochemistry
--------------------

Tissue sections from 3 WT and 3 *Entpd3 ^-/-^* mice were stained immunohistochemically as previously reported ( [@ref-45]). Antibodies used were: polyclonal sheep anti-mouse ENTPD3/CD39L3 (skin, 1:75; DRG and spinal cord 1:400; AF4464, R&D Systems), monoclonal mouse anti-NeuN (1:250; MAB377, Millipore), polyclonal chicken anti-Prostatic acid phosphatase (1:4,000; PAP, Aves Labs), polyclonal rabbit anti-NF200 (1:800; N4142, Sigma), monoclonal mouse anti-NF200 (Clone RT97; MAB5262, Millipore), polyclonal rabbit anti-CGRP (1:150; BML-CA1134, Enzo Life Sciences), polyclonal sheep anti-CGRP (1:300; BML-CA1137, Enzo Life Sciences); polyclonal rabbit anti-PKCγ (1:800; sc-211, Santa Cruz), and polyclonal rat anti-PECAM1/CD31 (1:400; Clone MEC 13.3, 553370, BD Biosciences). IB4 conjugated with Alexa Fluor dyes and secondary antibodies conjugated with Alexa Fluor dyes were purchased from Invitrogen. DRAQ5 (Catalog \# 4084) was purchased from Cell Signaling Technology. Stained sections were imaged on a Zeiss LSM 510 confocal microscope or a Zeiss LSM 710 confocal microscope.

Fast-Scan Cyclic Voltammetry (FSCV)
-----------------------------------

Mouse sagittal spinal cord slices were prepared as described previously ( [@ref-42]). In brief, male mice aged 1--2 months old (\~15 g; n=7 for each genotype) were anesthetized with urethane before decapitation, and the spinal cords were dissected and sectioned at 4°C in buffer that contained the following (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH ~2~PO ~4~, 26 NaHCO ~3~, 75 sucrose, 10 glucose, 1.5 ascorbic acid, 0.5 CaCl ~2~, 7 MgCl ~2~. The slices were then incubated for 45 minutes in artificial cerebrospinal fluid (ACSF), which contained the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH ~2~PO ~4~, 26 NaHCO ~3~, 25 glucose, 2.5 CaCl ~2~, 1.5 MgCl ~2~. All solutions were bubbled with 95%O ~2~/5%CO ~2~ for the duration of the dissection, incubation, and experiment steps.

FSCV monitoring of adenosine was performed as previously reported ( [@ref-42]), with the major difference being 100 µM ADP was used as the nucleotide substrate. Briefly, a disk-shaped carbon fiber microelectrode (Amoco) was inserted ( [@ref-9]), with the disk facing downwards, into the superficial dorsal horn. The potential of the microelectrode was scanned linearly at 400 V/s from -0.4 V to 1.5 V and back again once every 100 ms and was held at -0.4 V otherwise (all potentials versus Ag/AgCl). A micropipette inserted approximately 100 µm from the microelectrode was used to pressure-eject a bolus of 100 µM ADP using a Picospritzer ^®^ III (Parker Instrumentation, Pinebrook, NJ) (ejection parameters: 1 s, 20 PSI). The current was recorded for 5 ejections, 5 minutes apart, at the same location in each sample to obtain a mean response. The current was processed, as previously described ( [@ref-42]), using the background subtracted current at the voltammetric peak at \~1.0 V potential, which has been shown to be sensitive to adenosine and not to nucleotides, such as ATP, ADP, and AMP ( [@ref-43]).

Behavioral assays
-----------------

For all behavioral assays, \~3 month-old male WT (n=10) and *Entpd3 ^-/-^* (n=10; all mice weighing \~26 g) mice were tested in each assay. Mice were acclimated to handling, testing rooms and facilities prior to testing, and the experimenter was blinded to the genotype of each animal. Heat sensitivity was measured by heating each hindpaw once per day using the Plantar Test apparatus (IITC) with a cut-off time of 20 s. For the tail immersion assay, each mouse was gently restrained in a towel, and the distal one-third of the tail was immersed into a water bath heated to 46.5°C or 49°C or into 75% ethanol cooled to -10°C ( [@ref-49]). The latency to flick or withdraw the tail was measured once per mouse. The cut-off was set at 40 s, 30 s, and 60 s, respectively. For the hot plate test, the latency to jump, shake, or lick a hindpaw was measured within a 30 s cut-off time. To determine mechanical sensitivity, we used an electronic von Frey apparatus (IITC) with semi-flexible tips. Two measurements from each hindpaw were taken and averaged to determine the paw withdrawal threshold in grams. The tail clip assay (noxious mechanical) and cotton swab assay (innocuous mechanical) were performed as described ( [@ref-13]; [@ref-20]). For the acetone test ( [@ref-3]), each mouse was placed into a Plexiglas chamber with a wire mesh floor, 50 μL of acetone was placed onto the left hindpaw, and the time spent licking was measured for 1 minute. The cold plantar assay was performed with mice resting on the glass surface of the Plantar Test apparatus (IITC) ( [@ref-7]). For the two-temperature discrimination assay, each mouse was placed into a Plexiglas chamber covering two metal surfaces that could be set at different temperatures ( [@ref-3]; [@ref-11]). The amount of time mice spent on each side over a 10 minute period was recorded. Hot and cold sensitivity was assessed on a metal plate heated/cooled to a range of temperatures (5--55°C), with a cut-off time of 30 s, as described ( [@ref-14]). For measuring itch responses, histamine (10 μg/μL), chloroquine (CQ; 4 μg/μL) or β-alanine (20 μg/μL) dissolved in 0.9% saline was injected subcutaneously into the nape of the neck (50 μL injection volume). The number of scratching bouts was measured for 30 minutes in 5 minute blocks. One bout consisted of a set of scratches at the injection site until the hindpaw was either licked or placed onto the floor. For the water repulsion assay ( [@ref-50]), the mouse was immersed in a 37°C water bath for 2 min. The mouse was removed from the water and placed onto a paper towel for 5 s, then weight and rectal temperature (deep body temperature, Tb, measured using a digital thermometer, Acorn Temp TC Thermocouple) were measured every 5 min for 60 min. The Complete Freund's adjuvant (CFA) model of inflammatory pain and the lysophosphatidic acid (LPA) model of neuropathic pain were performed as described ( [@ref-38]; [@ref-56]). Twenty microliters of CFA was injected into the left hindpaw centrally beneath the glabrous skin, and 5 nmol of LPA was administered intrathecally.

Data analysis
=============

Data analysis was performed in Excel (version 2010) using t-tests for all behavioral studies and cell counts with all graphs created in GraphPad Prism. The FSCV data were analyzed using the analysis portion of the freely available software HDCV (Version 4). The software is available for download from: <http://www.chem.unc.edu/facilities/index.html?display=electronics&content=software>. Average peak currents from the FSCV data were compared using paired t-test. Significance was determined as p ≤ 0.05.

Results and discussion
======================

###### 

Please see the 'Legends' file in the zip file for descriptions of each data set.

###### 

Click here for additional data file.

ENTPD3 colocalizes with nociceptive and non-nociceptive neuronal markers in DRG
-------------------------------------------------------------------------------

ENTPD3 is expressed throughout the nervous system, including nociceptive neurons ( [@ref-4]; [@ref-19]; [@ref-48]). To determine which subsets of lumbar DRG neurons expressed ENTPD3, we immunostained for ENTPD3 and markers of nociceptive and non-nociceptive neurons. As previously reported ( [@ref-48]), most DRG neurons, including small-, medium-, and large-diameter neurons, showed some level of staining for ENTPD3 ( [Figure 2](#f2){ref-type="fig"}). For colocalization studies, we assessed only those neurons that were stained moderately to strongly for ENTPD3. All cells that expressed ENTPD3 also expressed NeuN, recapitulating previous results showing that ENTPD3 was primarily associated with neuronal cell types ( [Figure 2A--C](#f2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}) ( [@ref-4]; [@ref-19]; [@ref-48]). Conversely, 56.8% of all DRG neurons (identified by NeuN expression) labeled for ENTPD3 ( [Figure 2A--C](#f2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). PAP, a marker of nonpeptidergic and some peptidergic nociceptive neurons, was extensively colocalized with ENTPD3---the majority (72.7%) of DRG neurons expressing PAP also expressed ENTPD3, while almost half (43.5%) of all ENTPD3 ^+^ neurons expressed PAP ( [Figure 2D--F](#f2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). These results were similar to those found by Vongtau and co-workers, who reported that 97% of IB4-binding nonpeptidergic DRG neurons expressed ENTPD3 ( [@ref-48]). NF200, a marker for large-diameter, non-nociceptive neurons and smaller, thinly myelinated (Aδ) nociceptive neurons, colocalized with ENTPD3 ( [Figure 2G--I](#f2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}), suggesting that ENTPD3 was expressed by some non-nociceptive neurons. Finally, an antibody to CGRP was used to identify peptidergic neurons ( [Figure 2J--L](#f2){ref-type="fig"}). Of CGRP-expressing neurons, 48.7% were also positive for ENTPD3 ( [Table 1](#T1){ref-type="table"}). Thus, our results indicate that ENTPD3 is expressed in nociceptive and non-nociceptive neurons of the DRG.

![ENTPD3 is broadly expressed in DRG neurons.\
Mouse DRG neurons were immunostained for ENTPD3 ( **A**, **D**, **G**, **J**) and selected markers ( **B**, **E**, **H**, **K**). ( **C**, **F**, **I**, **L**) Merged images. Images were acquired by confocal microscopy. Scale bar: (in **L**) **A**-- **L** = 50 μM.](f1000research-3-5673-g0001){#f2}

###### Analysis of co-expression of ENTPD3 and markers in WT DRG.

  --------------------------------------------------------------------------------------------
              Percentage of ENTPD3 ^+^ neurons\        Percentage of marker ^+^ neurons\
              expressing indicated marker              expressing ENTPD3
  ----------- ---------------------------------------- ---------------------------------------
  **NeuN**    **100%**\                                **56.8 ± 2.4**\
              *(3,706 ENTPD3 ^+^ neurons evaluated)*   *(6,706 NeuN ^+^ neurons evaluated)*

  **PAP**     **43.5 ± 2.1**\                          **72.7 ± 1.4**\
              *(3,860 ENTPD3 ^+^ neurons evaluated)*   *(2,107 PAP ^+^ neurons evaluated)*

  **NF200**   **43.3 ± 2.3**\                          **60.9 ± 2.3**\
              *(3,706 ENTPD3 ^+^ neurons evaluated)*   *(2,589 NF200 ^+^ neurons evaluated)*

  **CGRP**    **19.9 ± 0.9**\                          **48.7 ± 3.2**\
              *(3,860 ENTPD3 ^+^ neurons evaluated)*   *(1,657 CGRP ^+^ neurons evaluated)*
  --------------------------------------------------------------------------------------------

n=3 animals per genotype; 5 sections per animal. Values represent pooled data from each genotype.

ENTPD3 expression in spinal dorsal horn
---------------------------------------

We also immunostained lumbar spinal cord sections to ascertain where ENTPD3 was located in the dorsal horn, the spinal region where axons of nociceptive and non-nociceptive sensory neurons terminate. ENTPD3 ^+^ nerve terminals were located primarily in lamina II, where IB4 terminals are located ( [Figure 3A--D,I](#f3){ref-type="fig"}), consistent with a previous report ( [@ref-48]). ENTPD3 ^+^ terminals also extended dorsally into lamina I, an area occupied by CGRP ^+^ terminals ( [Figure 3E,G,I](#f3){ref-type="fig"}) and ventrally into lamina III, an area with Protein Kinase Cγ (PKCγ)-expressing spinal neurons ( [Figure 3F,H,J](#f3){ref-type="fig"}). We also observed small ENTPD3 ^+^ spinal neurons in laminae I, II, and III ( [Figure 3A,B,G,H](#f3){ref-type="fig"}) as was reported by Vongtau and co-workers ( [@ref-48]). This localization pattern in spinal laminae and spinal neurons suggests that ENTPD3 might hydrolyze extracellular nucleotides in spinal pathways devoted to nociception and somatosensation.

![ENTPD3 is colocalized with peptidergic and nonpeptidergic markers in the dorsal horn of the spinal cord.\
Mouse lumbar spinal cord sections were immunostained for ENTPD3 ( **A**-- **B**), and for the indicated markers ( **C**-- **F**). ( **G**-- **J**) Merged images at high ( **G**-- **H**) and low ( **I**-- **J**) magnification. Scale bar in **H** ( **A**-- **H**) = 50 μM. Scale bar in **J** ( **I**-- **J**) = 100 μM.](f1000research-3-5673-g0002){#f3}

Generation and characterization of an *Entpd3 ^-/-^* mouse
----------------------------------------------------------

To assess the extent to which ENTPD3 was necessary for extracellular nucleotide hydrolysis, we disrupted the *Entpd3* gene by knocking a LoxP-flanked GFP construct into the start codon of ENTPD3 ( [Figure 4A](#f4){ref-type="fig"}). Expression of GFP was not detectable in DRG or spinal cord even when amplified with antibodies against GFP (image not shown). We were thus unable to use GFP to mark cells that expressed *Entpd3*. Using immunoblotting, we detected ENTPD3 protein in DRG and bladder (tissues known to express high levels of ENTPD3 ( [@ref-48]; [@ref-51])) from WT mice, but no ENTPD3 protein was detectable in tissues from *Entpd3 ^-/-^* mice ( [Figure 4B](#f4){ref-type="fig"}). These results confirmed that ENTPD3 protein was eliminated in our knockout line and that the antibody we used was specific for ENTPD3. We also immunohistochemically stained DRG, spinal cord, and hindpaw skin of WT and *Entpd3 ^-/-^* mice. We found that lumbar DRG sections from WT mice showed neuronal staining characteristic of ENTPD3, whereas sections from *Entpd3 ^-/-^* mice showed no staining ( [Figure 4C,F](#f4){ref-type="fig"}). Similarly, sections of lumbar spinal cord and hindpaw skin from *Entpd3 ^-/-^* mice showed none of the ENTPD3 ^+^ neural profiles observed in WT spinal cord and hindpaw skin ( [Figure 4D--E,G--H](#f4){ref-type="fig"}). Mice lacking ENTPD3 produced normal-sized litters (5--9 pups/litter) and had normal weights relative to WT mice (at 3 months \~26 g WT; \~27 g *Entpd3 ^-/-^*).

![ENTPD3 protein is eliminated in *Entpd3 ^-/-^* mice.\
( **A**) Cartoon depiction of the farnesylated GFP-DTR construct that was knocked-in to the start codon of *Entpd3*. ( **B**) Immunoblot showing loss of ENTPD3 protein in DRG and bladder collected from adult mice. ( **C**-- **H**) Loss of ENTPD3 in DRG ( **F**), spinal cord ( **G**), and glabrous skin ( **H**) in *Entpd3 ^-/-^* mouse tissue compared to wild-type tissues ( **C**, **D**, and **E**, respectively). Scale bars: **D** = 50 μM; **F** = 100 μM; **H** = 50 μM.](f1000research-3-5673-g0003){#f4}

Next, we used immunohistochemistry to determine if primary somatosensory neurons or axon terminals were affected by deletion of *Entpd3*. In DRG, the number of neurons that expressed nociceptive and non-nociceptive markers was not changed with the exception of a small, but statistically significant decrease in the number of neurons expressing NT5E ( [Table 2](#T2){ref-type="table"}). In WT mice, 35% of DRG neurons expressed NT5E, but in *Entpd3* ^-/-^ animals this percentage was reduced to 30.5% ( [Table 2](#T2){ref-type="table"}). We also used immunohistochemistry to assess whether the spinal dorsal horn of *Entpd3 ^-/-^* mice exhibited altered organization in comparison with that of WT animals. The laminar organization in the dorsal spinal cord of *Entpd3 ^-/-^* mice, as revealed by staining for CGRP and PKCγ and binding of IB4, was indistinguishable from that of WT mice ( [Figure 5](#f5){ref-type="fig"}), suggesting that there was no alteration in the organization of primary afferents or spinal neurons in the dorsal horns of mice that lack ENTPD3.

###### Marker analysis in WT and *Entpd3 ^-/-^* DRG sections.

  -----------------------------------------------------------------------------
              WT                          *Entpd3 ^-/-^*              p value
  ----------- --------------------------- --------------------------- ---------
  **PAP**     40.6% ± 2.0\                42.0% ± 1.8\                0.61
              (6,900 neurons evaluated)   (6,655 neurons evaluated)   

  **NF200**   39.8% ± 1.7\                37.1% ± 2.2\                0.33
              (6,706 neurons evaluated)   (7,574 neurons evaluated)   

  **NT5E**    35.2% ± 1.2\                30.5% ± 1.1\                0.0054
              (7,680 neurons evaluated)   (8,520 neurons evaluated)   

  **IB4**     32.0% ± 0.9\                33.0% ± 1.3\                0.55
              (6,828 neurons evaluated)   (7,008 neurons evaluated)   

  **CGRP**    30.9% ± 1.3\                27.6% ± 1.2\                0.079
              (6,828 neurons evaluated)   (7,008 neurons evaluated)   
  -----------------------------------------------------------------------------

n=3 animals per genotype; 6 sections evaluated per animal. Values represent pooled data from each genotype.

![Superficial dorsal horn organization in *Entpd3 ^-/-^* mice is normal.\
Sections of lumbar spinal cord from WT ( **A**) and *Entpd3* ^-/-^ ( **B**) mice were stained with antibodies to distinguish laminar organization of the superficial dorsal horn. Scale bar in **B** = 100 μM.](f1000research-3-5673-g0004){#f5}

Finally, to determine if cutaneous innervation was altered in *Entpd3 ^-/-^* mice, we co-stained sections of glabrous and hairy skin of WT and *Entpd3 ^-/-^* mice with antibodies to ENTPD3 and PGP9.5, a pan-neuronal marker ( [Figure 6](#f6){ref-type="fig"}). ENTPD3 marked most PGP9.5 ^+^ epidermal free nerve endings in hairy and glabrous skin as well as Meissner corpuscles and Merkel cells in volar pads ( [Figure 6A--F](#f6){ref-type="fig"}). These findings were similar to the previously reported staining pattern of ENTPD3 in skin sections ( [@ref-48]). Sections of skin from *Entpd3 ^-/-^* mice lacked all ENTPD3 staining. Expression of PGP9.5 was retained, revealing no differences in the density or structure of free nerve endings, Meissner corpuscles, and Merkel cells in *Entpd3 ^-/-^* mice compared to those observed in skin from WT mice ( [Figure 6G--L](#f6){ref-type="fig"}). Thus, cutaneous innervation was not altered by the loss of ENTPD3. Further, nerve fibers co-expressing ENTPD3 and PGP9.5 were found on blood vessels in the dermis and deep dermis of the hindpaw (image not shown). There was no difference in the density of innervation of blood vessels (as revealed by PGP9.5 immunostaining) between WT and *Entpd3 ^-/-^* mice (image not shown). Taken together, these results suggest that, with the exception of a small decrease in NT5E staining in DRG neurons, deletion of *Entpd3* did not affect afferents in the skin, DRG neurons, or primary somatosensory afferents in the dorsal spinal cord.

![Deletion of *Entpd3* does not affect the density of nerve fiber staining in skin.\
Sections of glabrous skin from the volar pads in WT ( **A**-- **F**) and *Entpd3 ^-/-^* ( **G**-- **L**) mice were stained with antibodies against ENTPD3 ( **A**, **D**, **G**, **J**) and PGP9.5 ( **B**, **E**, **H**, **K**). **D**-- **F** and **J**-- **L** are high magnification insets of **A**-- **C** and **G**-- **H** and show Meissner corpuscles. Scale bar in **I** ( **A**-- **C** and **G**-- **I**) = 100 μM. Scale bar in **L** ( **D**-- **F** and **J**-- **L**) = 50 μM.](f1000research-3-5673-g0005){#f6}

*Entpd3 ^-/-^* mice do not exhibit deficits in nucleotide hydrolysis or adenosine generation
--------------------------------------------------------------------------------------------

We previously reported that AMP hydrolysis in the DRG and dorsal spinal cord was redundantly carried out by three ectonucleotidases, PAP, NT5E, and TNAP ( [@ref-41]). However, the enzymes that contribute to ATP and ADP hydrolysis in DRG and spinal cord have not yet been fully characterized. To determine if ENTPD3 contributed to nucleotide hydrolysis in DRG, we performed histochemistry at a neutral pH (7.0) on DRG sections from WT and *Entpd3 ^-/-^* mice using the indicated nucleotides ( [Figure 7](#f7){ref-type="fig"}). AMP histochemical staining was found in cell bodies of small- and medium-diameter neurons ( [Figure 7A,D](#f7){ref-type="fig"}; where PAP and NT5E are located); ADP histochemical staining was strongest in blood vessels (where ENTPD1 is located) and on the membrane of most neurons ( [Figure 7B,E](#f7){ref-type="fig"}); and ATP histochemical staining was present on blood vessels and the cell membrane of most neurons ( [Figure 7C,F](#f7){ref-type="fig"}). These staining patterns matched what was previously seen in DRG sections from WT mice ( [@ref-39]; [@ref-42]; [@ref-48]; [@ref-56]).

![Nucleotide hydrolysis, assessed via enzyme histochemistry, is not reduced in DRG neurons from *Entpd3 ^-/-^* mice.\
DRG sections from WT ( **A**-- **C**) and *Entpd3 ^-/-^* ( **D**-- **F**) mice were stained using AMP ( **A**, **D**), ADP ( **B**, **E**), and ATP ( **C**, **F**) enzyme histochemistry at pH 7.0 in the presence of 20 mM MgCl ~2~. Concentration of nucleotides used for histochemistry were as follows: AMP, 6 mM; ADP, 1 mM; ATP, 0.1 mM; UTP, 0.1 mM. Scale bar in **F** = 50 μM.](f1000research-3-5673-g0006){#f7}

When comparing staining between WT and *Entpd3 ^-/-^* DRGs, we saw no difference in AMP histochemical staining ( [Figure 7A,D](#f7){ref-type="fig"}), consistent with the fact that AMP is not a substrate for ENTPD3 ( [@ref-10]). Surprisingly however, there were also no differences in histochemical staining between WT and *Entpd3 ^-/-^* DRGs when ADP or ATP was used as substrates ( [Figure 7B--C,E--F](#f7){ref-type="fig"}). These data suggest either that ENTPD3 does not hydrolyze these nucleotides in DRG or that other ADP- and ATP-hydrolyzing ectonucleotidases are present and function redundantly with ENTPD3. To determine if ENTPD3 hydrolyzed ADP and ATP redundantly with alkaline phosphatases at pH 7.0, we inhibited alkaline phosphatase activity in histochemical experiments with levamisole (10 mM). However, we observed no difference in staining between WT and *Entpd3 ^-/-^* DRGs in the presence of levamisole (image not shown). These data suggest DRG neurons contain additional ectonucleotidases besides TNAP and ENTPD3 that hydrolyze ATP and ADP at neutral pH.

We also found that enzyme histochemical staining was equivalent in the superficial dorsal spinal cord of WT and *Entpd3 ^-/-^* mice when the indicated nucleotides were used as substrates ( [Figure 8](#f8){ref-type="fig"}). Many ectonucleotidases, including ENTPD3 ( [@ref-23]), are slightly more active in biochemical assays with calcium as the divalent cation. However, we detected no difference in UTP histochemical activity in spinal cord between WT and *Entpd3 ^-/-^* mice when 2 mM or 20 mM CaCl ~2~ was substituted for 20 mM MgCl ~2~ ( [Figure 9](#f9){ref-type="fig"}; with deletion of ENTPD3 confirmed in these sections using immunostaining, [Figure 9H](#f9){ref-type="fig"}). Thus Mg ^2+^ and Ca ^2+^ appear to be interchangeable in this histochemical assay.

![Nucleotide hydrolysis is not reduced in spinal cord sections from *Entpd3 ^-/-^* mice.\
Lumbar spinal cord sections from WT ( **A**-- **D**) and *Entpd3 ^-/-^* ( **E**-- **H**) mice were stained using AMP ( **A**, **E**), ADP ( **B**, **F**), ATP ( **C**, **G**), and UTP ( **D**, **H**) enzyme histochemistry at pH 7.0 in the presence of 20 mM MgCl ~2~. Nucleotide concentrations were as follows: AMP, 3 mM; ADP, 1 mM; ATP, 0.2 mM; UTP, 0.2 mM. Scale bar in H = 200 μM.](f1000research-3-5673-g0007){#f8}

![UTP hydrolysis in spinal cord sections from WT and *Entpd3 ^-/-^* mice is unaffected by substitution of divalent cations in histochemistry procedure.\
Lumbar spinal cord sections from WT ( **A**-- **C**) and *Entpd3 ^-/-^* ( **E**-- **G**) mice were examined for UTP hydrolysis at pH 7.0 in the presence of either 2 mM CaCl ~2~ ( **A**, **E**), 20 mM CaCl ~2~ ( **B**, **F**), or 20 mM MgCl ~2~ ( **C**, **G**). UTP concentration for **A**-- **B** and **E**-- **F** is 0.2 mM and 0.1 mM for **C** and **G**. Representative images of ENTPD3 antibody staining in lumbar spinal cords from the same WT and *Entpd3 ^-/-^* mice are shown in **D** and **H**. Scalebar in **G**, **H** = 200 μM.](f1000research-3-5673-g0008){#f9}

To determine if other enzymes contributed to histochemical staining in the dorsal spinal cord when ATP and UTP (0.2 mM) were used as substrates, we used levamisole to block activity of alkaline phosphatases (10 mM), ouabain to block activity of Na ^+^/K ^+^-ATPase (5 mM), and ARL67156 (0.1 and 1 mM), an inhibitor of ENTPD1 and ENTPD3 ( [@ref-24]). The addition of these inhibitors did not result in any change in the staining intensity or pattern in the superficial dorsal horn of WT mice relative to *Entpd3 ^-/-^* mice, but adding ARL67156 caused a near-complete loss of histochemical staining in microglia in the spinal gray in both genotypes, presumably because of blockade of ENTPD1 activity ( [@ref-5]) (image not shown). Vongtau *et al.* also tested various inhibitors (ouabain, levamisole, and sodium azide) to block Na ^+^/K ^+^-ATPase, alkaline phosphatase, and ENTPD1 activity, respectively ( [@ref-48]). They found that none of these inhibitors affected ATP or UTP hydrolysis in the spinal cord and concluded that ENTPD3 might be responsible for the remaining staining. Our study demonstrates that the level of nucleotide histochemical staining was the same in the *Entpd3 ^-/-^* mice in the presence of ouabain and levamisole plus an ENTPD1/3 inhibitor (ARL67156), suggesting that one or more enzymes other than ENTPD3 are present that hydrolyze nucleotides in the spinal cord.

Enzyme histochemistry detects phosphate that is produced following nucleotide hydrolysis. As an alternative, we used FSCV to quantify adenosine production upon nucleotide hydrolysis in spinal cord slices of WT and *Entpd3 ^-/-^* mice. As previously reported, FSCV can be used to detect adenosine based on characteristic oxidation voltages at 1.0 and 1.5 V ( [@ref-43]). We applied 100 mM ADP to lamina II and then measured adenosine production at the tip of a carbon-fiber microelectrode ( [@ref-42]). Application of ADP led to the generation of adenosine in WT and *Entpd3 ^-/-^* mice, detected as an increase in measured current at oxidation voltages of 1.0 and 1.5 V ( [Figure 10A--B](#f10){ref-type="fig"}). Currents at 1.0 V were then converted to adenosine concentration. We then compared the peak adenosine concentration in WT and *Entpd3 ^-/-^* mice (n=5 slices/genotype) to determine if mice lacking ENTPD3 had any deficit in the production of adenosine ( [Figure 10C](#f10){ref-type="fig"}). We saw no significant differences in adenosine generation from ADP between spinal cord slices of WT and *Entpd3 ^-/-^* mice.

Note that FSCV cannot resolve neuronal ENTPD3 activity in the dorsal horn from spinal microglial ENTPD1 activity, so the adenosine detected by FSCV after applying ADP could originate from microglial ENTPD1 or other ectonucleotidases in the tissue. For example, this adenosine could originate from PAP and/or TNAP, as these enzymes are located in the same region and can also hydrolyze ADP to adenosine ( [Figure 1](#f1){ref-type="fig"}).

![Hydrolysis of ADP to adenosine is not reduced in *Entpd3 ^-/-^* mice.\
FSCV was used to measure adenosine production in response to a bolus of ADP. ( **A**) Representative FSCV color plots: 100 μM of ADP was pressure ejected for 1 s onto lamina II of ( **A**) WT or *Entpd3 ^-/-^* mice. ( **B**) Cyclic voltammogram of one voltage trace from -0.4 V to 1.5 V and back to -0.4 V confirms the production of adenosine in WT (black trace) and *Entpd3 ^-/-^* animals (blue trace) (shown as an increase in current at 1.0 and 1.5 V). ( **C**) Adenosine concentration calculated from 1.0 V current (white horizontal lines in **A**) in WT (black trace) and *Entpd3 ^-/-^* (blue trace) animals. There was no statistically significant difference between slices from WT and *Entpd3 ^-/-^* mice (n=5 slices for each condition; paired t-test).](f1000research-3-5673-g0009){#f10}

These FSCV results, when combined with enzyme histochemistry results, suggest that there are multiple ectonucleotidases that function redundantly to dephosphorylate ATP and ADP in DRG and superficial dorsal horn. Determining the molecular identities of these enzymes will require future studies with additional ectonucleotidase knockout mice and pharmacological inhibitors. Intriguingly, a redundant group of enzymes mediates AMP hydrolysis in the spinal cord, as PAP, NT5E, and TNAP must all be inhibited to completely block the generation of adenosine from AMP ( [@ref-41]). Likewise, TNAP can fully compensate for the loss of NT5E and generate adenosine from nucleotides in the hippocampus ( [@ref-52]).

Nociceptive behaviors are not impaired in *Entpd3 ^-/-^* mice
-------------------------------------------------------------

Given the high expression of ENTPD3 in nociceptive neurons, we examined whether loss of ENTPD3 affected nociceptive-related behaviors by testing heat, cold, mechanical, and itch sensation ( [Table 3](#T3){ref-type="table"}). In tests of heat sensitivity, there was no difference between WT and *Entpd3 ^-/-^* mice in the tail immersion assay (46.5°C or 49°C; [Table 3](#T3){ref-type="table"}). Similarly, there was no difference in withdrawal latency in the hot plate test ( [Table 3](#T3){ref-type="table"}). There was also no difference in responses between WT and *Entpd3* ^-/-^ mice in any of the cold assays (acetone evaporative cooling, cold tail immersion at -10°C, or cold plantar; [Table 3](#T3){ref-type="table"}). To further validate our thermal data, we used a hindpaw withdrawal assay ( [@ref-14]) that measures sensitivity to temperatures ranging from noxious cold to noxious hot ( [Figure 11A](#f11){ref-type="fig"}). No difference was found between WT and *Entpd3 ^-/-^* mice at any temperature. We also examined responses to mechanical stimuli and observed no difference between WT and *Entpd3 ^-/-^* mice in noxious mechanical (tail clip) and innocuous mechanical (cotton swab) assays ( [Table 3](#T3){ref-type="table"}).

###### Quantification of noxious heat-related, itch, and cold behavior assays.

  Behavior                         Response                   P Value
  -------------------------------- -------------------------- ---------
  **[*HEAT*]{.ul}**                                           
     **Tail Immersion (46.5°C)**   Latency to Flick (s)       
       Saline                      28.0 ± 1.8                 0.18
        *Entpd3 ^-/-^*             30.6 ± 2.1                 
     **Tail Immersion (49°C)**     Latency to Flick (s)       
       Saline                      8.6 ± 0.7                  0.47
        *Entpd3 ^-/-^*             8.7 ± 1.0                  
     **Hot Plate (52°C)**          Withdrawal Latency (s)     
       Saline                      30.2 ± 2.6                 0.19
        *Entpd3 ^-/-^*             26.3 ± 3.5                 
  **[*ITCH*]{.ul}**                                           
     **Histamine**                 Scratching Bouts           
       Saline                      107.3 ± 14.2               0.18
        *Entpd3 ^-/-^*             129.2 ± 18.5               
     **Chloroquine**               Scratching Bouts           
       Saline                      260.2 ± 52.5               0.48
        *Entpd3 ^-/-^*             263.0 ± 38.3               
     **β-Alanine**                 Scratching Bouts           
       Saline                      33.3 ± 5.6                 0.04
        *Entpd3 ^-/-^*             **21.9 ± 2.5\***           
  **[*COLD*]{.ul}**                                           
     **Acetone**                   Time Spent Licking (s)     
       Saline                      2.6 ± 0.7                  0.19
        *Entpd3 ^-/-^*             1.9 ± 0.4                  
     **Tail Immersion (-10°C)**    Latency to Flick (s)       
       Saline                      49.2 ± 3.2                 0.24
        *Entpd3 ^-/-^*             52.2 ± 2.7                 
     **Cold Plantar**              Withdrawal Latency (s)     
       Saline                      11.7 ± 0.5                 0.39
        *Entpd3 ^-/-^*             11.5 ± 0.4                 
  **[*MECHANICAL*]{.ul}**                                     
     **Cotton Swab**               Withdrawal Frequency (%)   
       Saline                      47.0 ± 8.5                 0.43
        *Entpd3 ^-/-^*             49.0 ± 6.6                 
     **Tail Clip**                 Latency to Bite Clip (s)   
       Saline                      8.2 ± 1.3                  0.20
        *Entpd3 ^-/-^*             6.9 ± 0.7                  

n = 10 mice/group, \*p \< 0.05.

![*Entpd3 ^-/-^* mice show no nociceptive or thermoregulatory behavioral deficits.\
( **A**) Sensitivity to temperatures ranging from noxious cold to noxious hot was measured using the hindpaw withdrawal assay. Cutoff time was 30 s. ( **B**) Two-choice temperature discrimination assay. Temperatures were maintained at 25°C/25°C, 25°C/30°C, 20°C/30°C, or 30°C/40°C, and time on each side was measured for 10 minute. ( **C** and **D**) The water repulsion assay examined rectal body temperature and body weight before and after immersion into a 37°C water bath for 2 min. ( **E**-- **H**) Mechanical allodynia and thermal hyperalgesia were measured in the LPA model of neuropathic pain ( **E** and **F**) and in the CFA model of inflammatory pain ( **G** and **H**). n=10 per group. t-tests were used to compare responses between genotypes at each time point, no significant differences detected. All values are represented as means ± SEM.](f1000research-3-5673-g0010){#f11}

To determine if loss of ENTPD3 affected itch, we injected pruritogens (histamine, chloroquine, β-alanine) into the nape of the neck and quantified scratching responses. Histamine- and chloroquine-mediated itch were not altered in *Entpd3 ^-/-^* mice compared to WT mice, but there was a statistically significant reduction (a decrease of 34%) in β-alanine-mediated itch ( [Table 3](#T3){ref-type="table"}). β-alanine activates the Mas-related G-protein-coupled receptor D (MRGPRD) in nonpeptidergic nociceptive neurons ( [@ref-25]; [@ref-31]; [@ref-37]). Therefore, it is possible that loss of ENTPD3 affects nonpeptidergic DRG neurons. When taken together, these data suggest that ENTPD3 does not play a widespread role in regulating sensitivity to noxious or innocuous somatosensory stimuli.

Temperature discrimination and thermoregulation are not impaired in *Entpd3 ^-/-^* mice
---------------------------------------------------------------------------------------

We next tested WT and *Entpd3 ^-/-^* mice in a two-temperature discrimination assay. In this assay, the amount of time spent in chambers with equal or different floor temperatures is quantified. Four temperature pairs were evaluated (25°C versus 25°C, 25°C versus 30°C, 20°C versus 30°C, and 30°C versus 40°C). There were no significant differences between WT and *Entpd3 ^-/-^* mice at any of the tested temperature pairs ( [Figure 11B](#f11){ref-type="fig"}). These data indicate that temperature discrimination is not impaired in *Entpd3 ^-/-^* mice.

We next examined the extent to which *Entpd3 ^-/-^* mice regulate body temperature in the water repulsion assay. Mice were placed in a 37°C water bath for 2 minutes and their core body (rectal) temperatures and body weights were measured every 5 minutes for 60 minutes after removal from the water bath ( [Figure 11C,D](#f11){ref-type="fig"}). Following removal from the water bath, WT and *Entpd3 ^-/-^* mice showed no differences in the initial body temperature increase or in the subsequent rate to recover their body temperature following hypothermia ( [Figure 11C](#f11){ref-type="fig"}). These data demonstrate that *Entpd3 ^-/-^* mice have no deficits in body temperature regulation due to evaporative cooling.

The water repulsion assay also tests fur barrier function ( [@ref-50]). Once the mouse is removed from the water bath, the initial increase in body weight is indicative of the amount of water absorbed by the fur. We found no significant difference between WT and *Entpd3 ^-/-^* mice in this assay ( [Figure 11D](#f11){ref-type="fig"}), including in the rate at which water is removed/evaporates from the mice.

Hyperalgesia and allodynia in *Entpd3 ^-/-^* mice are not impaired in models of chronic pain
--------------------------------------------------------------------------------------------

Lastly, we sought to determine if deletion of ENTPD3 affected the magnitude of allodynia and hyperalgesia in models of inflammatory pain and neuropathic pain. Lysophosphatidic acid (LPA) is a pronociceptive ligand that sensitizes nociceptors and produces a chemically-induced form of neuropathic pain when injected intrathecally (i.t.) ( [@ref-16]). Administration of CFA into the hindpaw causes thermal hyperalgesia and mechanical allodynia and serves as a model of inflammatory pain. We monitored thermal and mechanical sensitivity before and after administration of either LPA (i.t.) or CFA (into hindpaw) and observed no differences between WT and *Entpd3 ^-/-^* mice in either chronic pain model ( [Figure 11E,F](#f11){ref-type="fig"}).

Conclusions
===========

We generated a mouse that globally lacks ENTPD3 to evaluate the extent to which ENTPD3 was necessary for normal extracellular nucleotide hydrolysis in primary somatosensory neurons and dorsal spinal cord. Despite being expressed at high levels in many nociceptive and non-nociceptive somatosensory neurons, deletion of ENTPD3 did not affect extracellular nucleotide hydrolysis. Further, there were no changes in nociceptive behaviors in *Entpd3 ^-/-^* mice, though we did observe a small reduction in β-alanine-mediated itch response in knockout animals. These findings suggest that other enzymes are present that dephosphorylate extracellular nucleoside di- and triphosphates in primary somatosensory neurons. Our use of inhibitors ruled out the possibility that some ENTPDs, alkaline phosphatases and Na/K-ATPase compensated for the loss of ENTPD3. However, we cannot exclude the possibility that additional known or unknown enzymes with ectonucleotidase activity might be upregulated in *Entpd3 ^-/-^* mice and compensate for the loss of ENTPD3. Determining which enzymes act redundantly with ENTPD3 will require use of additional inhibitors and additional ectonucleotidase knockout lines. While ENTPD3 may function redundantly with other ectonucleotidases in these neurons, our *Entpd3* knockout line could prove useful in determining the physiological role of ENTPD3 in other organ systems where this ectonucleotidase is expressed, including in neurons that control wakefulness and feeding behavior ( [@ref-1]; [@ref-4]; [@ref-17]), in the cochlea ( [@ref-47]), in cells that regulate insulin secretion ( [@ref-21]; [@ref-44]), and in the gastrointestinal system ( [@ref-22]).

Data availability
=================

*F1000Research*: Dataset 1. Influence of ENTPD3 deletion on nucleotide hydrolysis in mouse primary somatosensory neurons and spinal cord: data, <http://dx.doi.org/10.5256/f1000research.4563.d31211> ( [@ref-27]).

We would like to thank JrGang Cheng and the Molecular Neuroscience Core at the UNC Neuroscience Center for generating the BAC targeting clone and Gabriela Salazar for technical assistance and help with managing the mouse colony.
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In this paper, McCoy *et al.* present novel results regarding the contribution of ENTPD3 to nucleotide hydrolysis in primary sensory neurons and the spinal cord. Immunohistochemical analysis of ENTPD3 distribution using a commercial antibody was highly similar to a previous report (full disclosure, from this reviewer's laboratory) cited in the paper; selectivity of the antibody was effectively confirmed using tissue from knockout mice generated by the authors. The study is well-executed and the figures are outstanding.

The key findings were generated through functional analysis of the knockout mice, including nucleotidase histochemistry, extensive behavioral analysis of nociceptive and non-nociceptive thresholds in naïve and inflamed mice, and fast-scan cyclic voltammetry (FSCV), an innovative method for measuring adenosine levels in situ in spinal cord slices. These studies found that ENTPD3 was dispensible for nucleotide hydrolysis, and all measured behavioral variables were unaltered in knockout mice, with the exception of a reduction in b-alanine-mediated itch behavior. The results suggest the possibility that additional ectonucleotidase(s) are co-expressed with ENTPD3 that are sufficient for normal nucleotide triphosphate/diphosphate hydrolysis, similar to the situation described by these authors for the ectonucleotidases that generate adenosine from AMP. The histological results support the conclusion that ENTPD3 is in position to impact both noxious and non-noxious somosensory transduction and transmission, but underscore that the regulation of somatosensory purinergic signaling is complex and likely to be regulated by multiple enzymes acting in tandem. This is a significant finding for the pain field, because ENTPD3 is the only ectonucleotidase identified in primary sensory neurons that regulates the availability of extracellular ATP and UTP, which have been extensively implicated in nociceptive signaling as agonists for P2X and P2Y receptors.

A key point not fully addressed here is whether knockout of ENTPD3 results in upregulation of other NTPDases in DRG neurons and/or dorsal horn, which could provide an explanation for the mild knockout phenotype. In particular, analysis of neuronal mRNA/ protein levels and distribution for ENTPD1, 2 and 8 in ENTPD3 knockout mice would increase the impact of the findings reported here. An intriguing possibility is that the alternate enzymes responsible are not members of the ENTPD family. The authors do demonstrate that the ENTPD1 inhibitor ARL67156 did not alter the distribution of enzyme histochemical staining in knockout tissue compared to WT, but  did eliminate microglial labeling in both genotypes.

One question that the authors might want to address in the discussion is how to evaluate whether FSCV is capable of resolving neuronal ENTPD3 activity in the dorsal horn when the neurons are surrounded by microglia expressing ENTPD1 (the active site of these enzymes is extracellular). As the authors suggest, further analysis in mice with multiple ENTPD gene deletions may be informative. However, the substantial behavioral evidence indicates that loss of ENTPD3 is not critical for normal sensory processing.
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We thank Dr. Molliver for his comments, particularly given his expertise in studying ENTPD3 in sensory neurons.  As Dr. Molliver notes, we attempted to address this issue of compensation using a number of inhibitors in combination with Entpd3-/- tissues.

Drs. Kirley and Molliver raised the question of whether other ectonucleotidases might be upregulated and compensate for the loss of ENTPD3.  We understand the rationale and interest behind this comment.  At this time, we feel such experiments are beyond the scope and focus of our initial study for the following reasons: If we were to find that other ecto-enzymes were upregulated, this information alone would not prove that any upregulated enzymes compensate or act redundantly in the absence of Entpd3.There are numerous ectonucleotidases (NTPDases, NPPs, alkaline phosphatases, acid phosphatases, Na/K-ATPases and likely additional enzymes with ectonucleotidase activity) that could be altered upon Entpd3 deletion.  We thus may miss the most relevant enzyme (or enzymes) if we focus on a candidate list.  Indeed, our attempt to focus on several candidates, via our use of inhibitors, was unsuccessful, suggesting this is a complex issue with multiple enzymes involved.   A genome-wide expression analysis would be more comprehensive but would not provide insights as to which upregulated genes are biologically relevant---knowing what genes change will not allow us to prove they compensate for the loss of Entpd3.Our study was not focused on examining potential compensatory mechanisms in the Enptd3-/- mice.  Such a study will require substantial effort to do properly (i.e. we would first need to identify all the enzymes that are upregulated and then demonstrate, in a systematic manner, that each one does or does not act redundantly using inhibitors and/or double/triple knockout mice).  Such an endeavor would require considerable effort. Thus, in lieu of examining a candidate list of ectonucleotidases, we felt a compromise would be to address this comment as follows (by revising the Conclusions section):

*"Our use of inhibitors ruled out the possibility that some ENTPDs, alkaline phosphatases and Na/K-ATPase compensated for the loss of ENTPD3.  However, we cannot exclude the possibility that additional known or unknown enzymes with ectonucleotidase activity might be upregulated in Entpd3-/- mice and compensate for the loss of ENTPD3.  Determining which enzymes act redundantly with ENTPD3 will require use of additional inhibitors and additional ectonucleotidase knockout lines."*

  

**Dr Molliver: **\"One question that the authors might want to address in the discussion is how to evaluate whether FSCV is capable of resolving neuronal ENTPD3 activity in the dorsal horn when the neurons are surrounded by microglia expressing ENTPD1 (the active site of these enzymes is extracellular). As the authors suggest, further analysis in mice with multiple ENTPD gene deletions may be informative. However, the substantial behavioral evidence indicates that loss of ENTPD3 is not critical for normal sensory processing.\"

To address this comment, we added the following sentence to the Results & Discussion section:

*"Note that FSCV cannot resolve neuronal ENTPD3 activity in the dorsal horn from spinal microglial ENTPD1 activity, so the adenosine detected by FSCV after applying ADP could originate from microglial ENTPD1 or other ectonucleotidases in the tissue.  For example, this adenosine could originate from PAP and/or TNAP, as these enzymes are located in the same region and can also hydrolyze ADP to adenosine (Figure 1)."*
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The paper by McCoy *at al.* entitled " *Deletion of ENTPD3 does not impair nucleotide hydrolysis in primary somatosensory neurons or spinal cord*" is a detailed and technically sound study. This paper focuses on possible roles for ENTPD3/NTPDase3 in pain perception and neural transmission in the dorsal root ganglia (DRG) and spinal cord. In addition, other proteins of interest that are related and known to be involved in the DRG, including prosthetic acid phosphatase (PAP), 5'-nucleotidase (NT5E) and tissue nonspecific acid phosphatase (TNAP) were examined. Many behavioral and pain assays were performed. These include tail immersion assays, a hot plate test, tail clip assay, cotton swab assay, acetone test, cold plantar assay, and 2-temperature discrimination assays. In addition, several assays for itch were performed, including histamine, chloroquine, and beta-alanine induced itch. Also, several other behavioral assays, including the water repulsion assay, the Complete Freund's Adjuvant (CFA) inflammation pain assay and the LysoPhosphatidic Acid (LPA) neuropathic pain assays were performed.

In general, the work is well done and detailed, and includes the appropriate controls. However, the main problem with this work is that there is no indication of the physiological function of NTPDase3/ENTPD3 revealed by any of the experimental results. Of course, negative data is sometimes important, and this is so in this case. However, what is really missing from this work is analysis for other nucleotidases that are likely to compensate for the loss of NTPDase3 in these mice. These include the nucleotide pyrophosphatase/phosphodiesterase enzymes (NPPs), and more importantly, the other members of the cell-surface NTPDase class of nucleotidases, especially NTPDase1/ENTPD1, and NTPDase2/ENTPD2.  Since the authors claim in their abstract that " *there could be multiple ectonucleotidases that act redundantly to hydrolyze nucleotides in these regions of the nervous system*" (which seems logical and likely), it is somewhat curious that no analyses for these other nucleotidases were performed. If such experiments were done, and if up-regulation of one or more of these enzymes was observed, this study would be more interesting, and the paper more important, since this might suggest putative physiological role(s) for NTPDase3/ENTPD1.

There are a couple of interesting and possibly problematic experimental details reported in the paper. First, why was 20 mM magnesium chloride used in the enzyme histochemistry experiments? This seems to be an unreasonably high, non-physiologic, concentration of magnesium. In addition, many of these nucleotidases, including NTPDase3 and other NTPDases, are, in fact, more active using calcium as a divalent cation as opposed to magnesium. So the choice of 20 mM magnesium chloride seems odd. Also, one change in these knockout mice that is noted in terms of possible effects on nucleotide hydrolysis is the decrease in 5'-nucleotidase protein seen in the DRG neurons of the knockout mouse, which is reported in Table 2. However, as reported in Figure 7, there is no apparent decrease in hydrolysis of AMP in the same dorsal root ganglia, which is apparently not consistent with Table 2, although other enzymes could come into play (but don't seem to change in the KO). However, enzyme histochemistry is difficult to accurately quantitate and is usually regarded as a semi-quantitative technique. Thus, a relatively small change in hydrolysis rates may not be evident from enzyme histochemical data. This is a potential problem with Figure 7, and begs the question as to why tissue homogenates were not evaluated by solution-based, quantitative nucleotidase enzyme assays. The same limitations are applicable to the data reported in Figure 8 on spinal cord sections from wild type and knockout mice. As reported in Table 3, the authors did find a significant difference in itch response to beta-alanine in the KO mice. However, again, the other itch data, and the rest of the data in Table 3, show no difference between wt and KO mice for responses to itch, heat, or cold behavioral stimuli.

In their conclusion section, the authors do mention other roles that have been suggested for NTPDase3/ENTPD3, including possible roles in the hypothalamus for controlling wakefulness and feeding behavior, for hearing in the cochlea, in the beta cells of the pancreas for regulation of ATP-controlled insulin secretion, and in the G.I. tract. It would be interesting to report any experiments designed to monitor for changes in any of these putative physiological functions of NTPDase3. These could include measurements designed to detect abnormal sleep times or cycles, abnormal eating habits, and abnormal plasma glucose and insulin levels and/or abnormal responses to glucose tolerance tests.

In conclusion, this study is well done and thorough with respect to the attributes that were evaluated in the DRG and spinal cord. Unfortunately, the results do not suggest likely physiological function(s) for NTPDase3/ENTPD3. Also, there is no data reported for other related cell-surface nucleotidases, such as NTPDases 1 and 2, which may be up-regulated in a compensatory response to the knockout of NTPDase3. In addition, there is no mention of experiments designed to address other putative physiological functions of NTPDase3, which are not related to the DRG or spinal cord. Hopefully, these points will be addressed in future work on these knockout animals.
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We thank Dr. Kirley for his comments and for appreciating that our study, which is focused on Entpd3 in sensory neurons and spinal cord, largely reports negative findings.  This marks the first reported Entpd3 knockout mouse.  A priori, it was unknown if this ectonucleotidase would affect nucleotide hydrolysis in sensory neurons or spinal cord independent of the other ectonucleotidases that are present in these tissues. 

Since deletion of Entpd3 had no effect on nucleotide hydrolysis, we performed additional analyses to determine if other ectonucleotidases were involved.  This includes assessing whether alkaline phosphatases act redundantly with Entpd3 (using the inhibitor levamisole), assessing whether other Entpds act redundantly with Entpd3 (using the nonselective Entpd inhibitor ARL67156), and assessing whether Na/K-ATPases act redundantly with Entpd3 (using ouabain to inhibit these ATPases).  The outcomes of these experiments are described in the results section.

Drs. Kirley and Molliver raised the question of whether other ectonucleotidases might be upregulated and compensate for the loss of ENTPD3.  We understand the rationale and interest behind this comment.  At this time, we feel such experiments are beyond the scope and focus of our initial study for the following reasons: If we were to find that other ecto-enzymes were upregulated, this information alone would not prove that any upregulated enzymes compensate or act redundantly in the absence of Entpd3.There are numerous ectonucleotidases (NTPDases, NPPs, alkaline phosphatases, acid phosphatases, Na/K-ATPases and likely additional enzymes with ectonucleotidase activity) that could be altered upon Entpd3 deletion. We thus may miss the most relevant enzyme (or enzymes) if we focus on a candidate list.  Indeed, our attempt to focus on several candidates, via our use of inhibitors, was unsuccessful, suggesting this is a complex issue with multiple enzymes involved.   A genome-wide expression analysis would be more comprehensive but would not provide insights as to which upregulated genes are biologically relevant---knowing what genes change will not allow us to prove they compensate for the loss of Entpd3.Our study was not focused on examining potential compensatory mechanisms in the Enptd3-/- mice.  Such a study will require substantial effort to do properly (i.e. we would first need to identify all the enzymes that are upregulated and then demonstrate, in a systematic manner, that each one does or does not act redundantly using inhibitors and/or double/triple knockout mice).  Such an endeavor would require considerable effort.  For example, it took us several years and multiple knockout lines to rigorously demonstrate that PAP, NT5E and TNAP act redundantly to generate adenosine from AMP. Thus, in lieu of examining a candidate list of ectonucleotidases, we felt a compromise would be to address this comment as follows (by revising the Conclusions section):

* "Our use of inhibitors ruled out the possibility that some ENTPDs, alkaline phosphatases and Na/K-ATPase compensated for the loss of ENTPD3.  However, we cannot exclude the possibility that additional known or unknown enzymes with ectonucleotidase activity might be upregulated in Entpd3-/- mice and compensate for the loss of ENTPD3.  Determining which enzymes act redundantly with ENTPD3 will require use of additional inhibitors and additional ectonucleotidase knockout lines."*

**Dr Kirley:** \"There are a couple of interesting and possibly problematic experimental details reported in the paper. First, why was 20 mM magnesium chloride used in the enzyme histochemistry experiments? This seems to be an unreasonably high, non-physiologic, concentration of magnesium. In addition, many of these nucleotidases, including NTPDase3 and other NTPDases, are, in fact, more active using calcium as a divalent cation as opposed to magnesium. So the choice of 20 mM magnesium chloride seems odd.\"

To address this comment, we performed new experiments.  We performed histochemistry experiments with 2 mM CaCl ~2~, 20 mM CaCl ~2~ and 20 mM MgCl ~2~, in WT and Entpd3-/- mice.  These data are shown in new Figure 9.

We also updated the results to include this new information:

*"Many ectonucleotidases, including ENTPD3 (Lavoie et al reference: PMID: 15130768; currently ref \#23 "Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-3"), are slightly more active in biochemical assays with calcium as the divalent cation.  However, we detected no difference in UTP histochemical activity in spinal cord between WT and Entpd3-/- mice when 2 mM or 20 mM CaCl ~2~was substituted for 20 mM MgCl ~2~ (Figure 9; with deletion of ENTPD3 confirmed in these sections using immunostaining, Figure 9H).  Thus Mg ^2+^and Ca ^2+^ appear to be interchangeable in this histochemical assay." *

Also please note, we used 20 mM MgCl in our histochemical experiments because a previous study, which we based our histochemistry method on, found that ATP ectonucleotidase activity in skin Langerhans cells was divavelent cation dependent, with complete interchangability between Ca ^2+^ and Mg ^2+^, and with optimal staining at a 20 mM concentration of either divalent (see [Chaker *et al.*, 1984](http://www.ncbi.nlm.nih.gov/pubmed/6150959)).  20 mM MgCl ~2~ or 20 mM CaCl ~2~ thus appears to be optimal for ATP histochemical staining.  And in biochemical assays with ENTPDs, Mg ^2+^ and Ca ^2+^ were interchangeable when ATP and ADP were used as substrates ( [Rucker *et al.*, 2008](http://www.ncbi.nlm.nih.gov/pubmed/18201730)).

**Dr Kirley: **\"Also, one change in these knockout mice that is noted in terms of possible effects on nucleotide hydrolysis is the decrease in 5'-nucleotidase protein seen in the DRG neurons of the knockout mouse, which is reported in Table 2. However, as reported in Figure 7, there is no apparent decrease in hydrolysis of AMP in the same dorsal root ganglia, which is apparently not consistent with Table 2, although other enzymes could come into play (but don't seem to change in the KO). However, enzyme histochemistry is difficult to accurately quantitate and is usually regarded as a semi-quantitative technique. Thus, a relatively small change in hydrolysis rates may not be evident from enzyme histochemical data. This is a potential problem with Figure 7, and begs the question as to why tissue homogenates were not evaluated by solution-based, quantitative nucleotidase enzyme assays. The same limitations are applicable to the data reported in Figure 8 on spinal cord sections from wild type and knockout mice.\"

We agree that histochemical staining provides a semi-quantitative readout of enzyme activity.  This is why we turned to FSCV in spinal cord slices.  FSCV provides a quantitative electrochemical method for measuring hydrolysis of ADP to adenosine, in the precise anatomical region where Entpd3 is located.  Since we found no differences between WT and Entpd3-/- mice using this quantitative electrochemical technique, we feel these data are sufficient to show that loss of Entpd3 alone has no measurable effect on nucleotide hydrolysis. 

And, as can be seen from our micrographs, Entpd3 is restricted to the dorsal spinal cord while ATP and ADP histochemical activity is broadly distributed. Use of a solution-based assay would entail creating homogenates from spinal cord or DRG, thus disrupting the integrity of the tissue and introducing more ectonucleotidases into the assay (which would reduce signal-to-noise).

The small 4.5% reduction in NT5E in DRG was statistically significant, although it appears to have no effect on AMP hydrolysis, as assessed histochemically.  This likely reflects that AMP can be hydrolyzed by NT5E, PAP and TNAP, as we previously found.  Since this did not constitute a major finding, we did not focus or discuss this in the text. 

**Dr Kirley: \"**As reported in Table 3, the authors did find a significant difference in itch response to beta-alanine in the KO mice. However, again, the other itch data, and the rest of the data in Table 3, show no difference between wt and KO mice for responses to itch, heat, or cold behavioral stimuli.\"

We felt it would be difficult to experimentally pursue the mechanistic basis for this itch phenotype because it was extremely small in magnitude.  Such small behavioral effects are not easy to pursue.  Moreover, it was the only sensory phenotype out of a large number of sensory functions we probed, suggesting it is a very mild sensory phenotype.

**Dr Kirley: \"**In their conclusion section, the authors do mention other roles that have been suggested for NTPDase3/ENTPD3, including possible roles in the hypothalamus for controlling wakefulness and feeding behavior, for hearing in the cochlea, in the beta cells of the pancreas for regulation of ATP-controlled insulin secretion, and in the G.I. tract. It would be interesting to report any experiments designed to monitor for changes in any of these putative physiological functions of NTPDase3. These could include measurements designed to detect abnormal sleep times or cycles, abnormal eating habits, and abnormal plasma glucose and insulin levels and/or abnormal responses to glucose tolerance tests.\"

These are indeed interesting topics for future study.  However, we feel they are beyond scope of our present study, which is focused on examining the function of Entpd3 in primary somatosensory neurons and dorsal spinal cord.

**Dr Kirley:**\"In conclusion, this study is well done and thorough with respect to the attributes that were evaluated in the DRG and spinal cord. Unfortunately, the results do not suggest likely physiological function(s) for NTPDase3/ENTPD3. Also, there is no data reported for other related cell-surface nucleotidases, such as NTPDases 1 and 2, which may be up-regulated in a compensatory response to the knockout of NTPDase3. In addition, there is no mention of experiments designed to address other putative physiological functions of NTPDase3, which are not related to the DRG or spinal cord. Hopefully, these points will be addressed in future work on these knockout animals.\"

We agree that future studies are warranted.  By reporting our findings with these first ever Entpd3 knockout mice, it will now be possible for us and others to study Entpd3 in other physiological contexts and to explore possible compensatory mechanisms.
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